Another biopharma tried buying Amicus before BioMarin's $4.8B deal
在BioMarin达成48亿美元交易前，另一家生物医药公司曾尝试收购爱美医疗

The road to Amicus Therapeutics’ $4.8 billion exit to BioMarin last month included a previously undisclosed acquisition offer from another biopharma, quiet dinners between CEOs and a months-long push to settle a legal dispute.
爱美医疗上月以48亿美元卖身给BioMarin的历程，曾包括一家未披露的生物医药公司发来的收购要约、两位首席执行官之间的私下晚宴，以及为解决一场法律纠纷而持续数月的努力。